BrachyDOSE 2025 review

12/15/2025

Another year full of events, meetings, pitching sessions, and hard work have passed. Let’s recap the most important BrachyDOSE moments of 2025.

Brachydose team were active participants of industry events all around the globe. From startup pitching competitions to big international summits. BrachyDOSE started 2025 by attending biggest startup events in the Baltic States, flying to the international conferences and even the United States of America.

During 2025 we attended 13 pitching and networking events:

sTARTUp Day 2025 in Tartu (Estonia).
TechChill in Riga (Latvia).
EIC summit in Brussels (Belgium).
LOGIN conference in Vilnius (Lithuania).
BSV Ventures portfolio showcase in Vilnius (Lithuania).
Life Sciences Baltics conference in Vilnius (Lithuania).
Startup Fair. Pulse in Vilnius (Lithuania).
Startup World Cup Grand Finale in San Francisco, CA (USA)
Deep Tech CEE Summit in Warsaw (Poland).
Inovatorių pusryčiai in Kaunas (Lithuania).
Jumpstarter NEXT program grand finale in Budapest (Hungary), which is a part of EIT Innovation Awards 2025.
Kaunas startup Awards 2025 in Kaunas (Lithuania)
EIT Health Morning Health Talks in Kaunas (Lithuania).

Science is the core of the deep-tech! Our CEO Neringa mentored in two healthtech related Hachathons:

Cassini Hackathon in Vilnius (Lithuania).
Flaming Shield: Mission AI 2025 hackathon in Kaunas (Lithuania).

We attended a medical physics conference:

Medical Physics in the Baltic States conference in Kaunas (Lithuania).

These three programs helped to accelerate the growth of our startup throughout 2025:

Tech-Park Kaunas pre-acceleration program. The program started on April 14th and continued until June 19th.
atTRACTION first customer acceleration program, which took 5 weeks. We participated in this program together with Kaunas University of Technology Department of Physics.
EIT Jumpstarter NEXT programme

Health2Innovation program

We helped to create a program for students and also attended Health2Innovation Bootcamp on 10-11th December in Lund (Sweden).

Data Pilot

We are happy that we had an opportunity to receive secondary data of Lithuanian cancer patients. We were the first startup to get a permission to analyze that data. This analysis allowed us to better understand the costs associated with cancer patients in the Lithuanian health system and adjust our business assumptions. Also, a whitepaper was released by Inga Kanapeckienė: Lithuania Data Pilot project: Providing secondary use of health data to early stage startups

Company’s growth

From a business development perspective, we made steady progress throughout 2025. We have filed an EU patent application, secured a seed investment, and passed the biocompatibility tests.

IP protected

Applied for a patent: A SYSTEM FOR MONITORING A RADIOTHERAPY DOSE. No.: EP25160770.1 Date: 2025-02-27.

Investment received

€554 000 seed investment received. The deal includes Coinvest Capital, BSV Ventures, and business angels’ networks LitBAN and EstBAN.

Biocompatibility assessment

BrachyDOSE successfully passed all relevant biocompatibility tests for the tube-shaped sensor.

New partnership agreement

We signed an R&D partnership agreement with Klaipėda University Hospital. This partnership will be a step forward for science and business collaborations.

Awards and recognition

Up to €50,000 in investment from the Estonian Business Angels Network (EstBAN) that was included into the €554k investment.
1st place at EIT Jumpstarted Next program.

Brachydose in Media

During 2025 BrachyDOSE name visible in Lithuanian and international press. The most important interviews and news articles are listed below:

Our CEO Neringa was talking on EIT Innostars Talks Podcast. You can listen to the podcast here.
Delfi diena interview with our CEO Neringa during Startup Fair 2025.
MedTech startup BrachyDOSE has successfully secured an investment of EUR 0.5 million
Startup BrachyDOSE to Use €0.5 Million Investment to Advance Cancer Treatment Technology
Sėkmė be „feilų“ – neįmanoma? Startuolių kūrėjai įsitikinę: sunkumus galima paversti galimybėmis
The reinvention of cancer care. BrachDOSE, real-time radiation data, and the rise of Baltic medtech

What to expect in 2026

We plan next year to be full of intensive work towards our goals. As we are currently working on CE/MDR documentation and expect to complete them in 2026. Having CE/MDR certification will allow us to start selling our solution to first adopters. First sales will lift us to the next level.